maybe?
imo, there's not enough regulation regarding these private equity investment- and venture capital fincancing-type entities which the Carlyle-Blackstone-Poppy-Baker folks seem to fancy
Cogene BioTech Ventures is a life sciences and medical technology venture capital firm based in Houston, Texas. Cogene's core business is based on early-stage and middle-stage venture investing across the broad spectrum of life sciences, including biopharmaceuticals and biotechnology platforms that enable better, faster and cheaper therapeutic drug discovery. Other areas of investment focus include bionanotechnology, therapeutic medical devices and health care IT / software.
As a life science fund, Cogene considers later-stage private equity investments in the life sciences and medical technology sectors. Investment sizes in the current portfolio companies range from $200K to $5M.
http://www.cogenebiotech.com/http://www.cogenebiotech.com/portfolio.htmconsists of:
Athersys
EnVivo Pharmaceuticals
Genesis Park
Kodiak Technologies, Inc.
Lexicon Genetics
Macrogenics
Odyssey Thera, Inc.
Opexa Pharmaceuticals
Raven Biotechnologies, Inc.
Targacept, Inc.
Xeotron Corporation
Two Houston scientists join Brown Foundation IMM as adjunct faculty
Two distinguished Houston scientists have been appointed adjunct professors at The University of Texas Health Science Center at Houston and at its Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, said James T. Willerson, M.D., president, Monday.
C. Thomas Caskey, M.D., and Neal F. Lane, Ph.D., were invited to serve as adjunct professors by Willerson and Ferid Murad, M.D., Ph.D., Nobel laureate and director of the Brown Foundation IMM and its Research Center for Cellular Signaling. Caskey, a member of the National Academy of Sciences, and Lane, a member of the American Academy of Arts and Sciences, also will work with the Scientific Advisory Board of the Brown Foundation IMM.
"These two scientists have highly respected records of distinguished accomplishments in their respective fields, and we highly value their ability to help us in developing research programs and recruiting top scientists to our institution in the areas we plan to pursue in the fight against mankind's most persistent diseases," Willerson said.
Caskey is president and chief executive officer of
Cogene Biotech Ventures, a life sciences and medical technology venture capital firm based in Houston. Lane is the Edward A. and Hermena Hancock Kelly University Professor at
Rice University. He also is a Senior Fellow of the James A. Baker III Institute for Public Policy.
http://newsonthego.uthouston.edu/archive/2004/nog258/